While
I love to tell you all about progress in treating brain tumors, I think it’s
equally important to repost news like the NBTS’s comments on the Avastin
Clinical trials.
“National
Brain Tumor Society is deeply disappointed in the recently announced results of
the AVAglio clinical trial. This trial revealed that Avastin (in combination
with standard of care treatments) did not significantly prolong the lives of
newly diagnosed GBM patients.
We
are equally concerned with additional findings from a large, National Cancer
Institute (NCI)-supported clinical trial conducted by the Radiation Therapy
Oncology Group (RTOG). Similar to the AVAglio trial, the RTOG study did not
show statistically significant increases in overall survival for newly
diagnosed GBM patients taking Avastin in combination with standard of care
treatments. Data from the AVAglio and RTOG studies collectively have provided
mixed results on issues such as progression-free survival (i.e. a measure of
tumor growth in response to a therapy) and quality of life, which will require
careful and further analysis to better understand their full meaning in terms
of patient care.”
You
can read the full article here: http://www.braintumor.org/news/latest-nbts-news/nationalbraintumorsocietyrespondstoresultsofavastinclinicaltrials.html
No comments:
Post a Comment